Supernus Pharmaceuticals, Inc.

Industry

  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release

Other Names/Subsidiaries

  • Adamas Pharmaceuticals, Inc.
  • Biscayne Neurotherapeutics, Inc.
  • Biscayne Neurotherapeutics Australia Pty, Ltd
  • Shire plc
  • Shire Laboratories Inc
See more in Biomedtracker

Latest on Supernus Pharmaceuticals, Inc.

Scrip

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Sage Therapeutics appears to have finally secured a palatable exit for investors after facing R&D setbacks and cost cuts and rejecting an initial buyout offer from its Zurzuvae (zuranolone) commer

Pink Sheet

As US FDA Communications Freeze Thaws, Approvals Accumulate

 
• By Bridget Silverman

The US Food and Drug Administration is starting to post information to key drug databases on its website again after most of its public communications were halted 21 January. The Center for Drug Evalu

Scrip

AbbVie Gets Second Parkinson’s Drug With Vyalev Approval

 
• By Joseph Haas

After a quick resolution of a manufacturing-related complete response letter, AbbVie Inc. has the next piece in place for its Parkinson’s disease franchise. The US Food and Drug Administration cleared

Pink Sheet

Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications

 
• By Bridget Silverman

Rare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions